Rare Disease Day (www.rarediseaseday.org) was established by EURORDIS in 2008 and takes place on the last day of February each year to raise global awareness of the risk and impact of rare diseases. The global theme for Rare Disease Day 2020 is “Reframe Rare,” highlighting the need to address many of the misconceptions about rare diseases. Throughout February, Albireo has presented insights and shareable content from families affected by rare cholestatic liver diseases on the company’s social media platforms.
“Rare Disease Day is an important opportunity to shed light on the extreme physical, social and psychological burdens that people affected by rare diseases face, and to join with patients, families and healthcare professionals around the world in building awareness and understanding,” said
Albireo employees will also participate in Rare Disease Day 2020 activities to show their support for all patients and families affected by cholestatic liver diseases. The company will host meetings in their
“We hope that everyone will take an opportunity to help family, friends, healthcare providers and others to learn more about the impact of rare diseases by sharing their experience on social media,” said
“Feeling isolated is a common experience in the rare disease community, especially when you are dealing with rare liver disease,” said
For information and about progressive familial intrahepatic cholestasis (PFIC), visit PFIC.org; Alagille syndrome, visit Alagille.org; biliary atresia, visit childliverdisease.org; and primary sclerosing cholangitis (PSC) visit pscpartners.org.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo’s clinical pipeline also includes two Phase 2 product candidates. Albireo’s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world.
To hear perspectives from families affected by PFIC, visit www.pficvoices.com.
Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is based in Boston, Mass., and its key operating subsidiary is in Gothenburg,
Source: Albireo Pharma, Inc.